A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999.
暂无分享,去创建一个
S. Lawson-Ayayi | P. Morlat | F. Dabis | F. Djossou | D. Malvy | R. Thiébaut | F. Bonnet | D. Lacoste | J. Beylot | N. Bernard | R. Ramanampamonjy | M. Bonarek
[1] V. Soriano,et al. Liver toxicity caused by nevirapine. , 2002, AIDS.
[2] B Clotet,et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile , 2001, AIDS.
[3] J. Miro,et al. Rapid Communications: Failure of a Short‐Term Prednisone Regimen to Prevent Nevirapine‐Associated Rash: A Double‐Blind Placebo‐Controlled Trial: The GESIDA 09/99 Study , 2001, Journal of acquired immune deficiency syndromes.
[4] G. Ippolito,et al. Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. , 2001, AIDS.
[5] D. Bangsberg,et al. Adverse effects of nevirapine , 2001, The Lancet.
[6] Andrew Phillips,et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy , 2001, AIDS.
[7] Geoffrey Scott,et al. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1 , 2001, The Lancet.
[8] Stuart Johnson,et al. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. , 2000, JAMA.
[9] V. Soriano,et al. Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids , 2000, AIDS.
[10] H. Ochs,et al. Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage ΦX174 in asymptomatic HIV-1 infected patients , 2000, AIDS.
[11] P. Couzigou,et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA). , 1999, AIDS.
[12] J. Lang,et al. Prednisolone does not prevent the occurrence of nevirapine-induced rashes. , 1999, AIDS.
[13] P. Cadrobbi,et al. Severe hepatic failure related to nevirapine treatment. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] J. Gatell,et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. , 1999, AIDS.
[15] J. Montaner,et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.
[16] R. Salamon,et al. [Human immunodeficiency virus infection and AIDS in Aquitaine. 10 years' experience of a hospital information system, 1985-1995. Le Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA)]. , 1997, Presse medicale.
[17] M. Niu,et al. Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection , 1996, Annals of Internal Medicine.
[18] D. Cooper,et al. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV‐infected patients , 1996, AIDS.
[19] D. Francisci,et al. A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[20] J. Montaner,et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.